Pipe line
We respond to changes.

CLINICAL TRIAL

OUR PIPELINE MAKING THE GREAT, GREATER

  • pipe_arrow_gray

    2017 ~ 2018

  • pipe_arrow_gray

    2019

  • pipe_arrow_gray

    2020

  • pipe_arrow_gray

    2021+

  • Oral GLP-1 gene delivery for type II diabetes
  • 300 million
    patients
    with diabetes
  • Oral GLA gene delivery for treatment of Gaucher & Fabry
  • Rare disease
    treatment costs
    200 million won
    /1person/1yr
  • Oral parathyroid hormone (PTH ) delivery for osteoporosis
  • 200 million
    patients
    with osteoporosis
  • Oral micro RNA/siRNA delivery for reverse aging
    • Basic discovery with KAIST
    • Development
  • Anti-aging

효율적인 투자 및 연구개발을 통한 성장 로드맵

  • Non-clinical study for
    oral diabetic therapy
  • 600 million won of
    government investment
  • Rare disease pipeline
    development
  • Investment plan with
    investors
  • Primates study
  • Preparation of clinical trial
  • Expand company
    into the US through
    Global CRO
  • Investment attraction
    (clinical costs)
  • Development of next
    generation obesity
    treatment
  • R&D center construction
    (Pangyo)
  • Clinical trials (>3 case)
  • Attracting series
    investment
  • L/O or Co-development
    with global
    pharmaceutical company
  • Development of oral
    anti-aging agent
  • Development of
    oral vaccine
  • Complete Oral Platform
  • World's first global oral
    medicine company
  • Stable growth through
    basic research and big
    investment
  • 2018 ~ 2019
  • 2020 ~ 2021
  • 2022 ~ 2023
  • 2024 ~ 2025
  • 2026 ~
  • 회사가치
    100~200억
  • pipe_arrow_long
  • 회사가치
    1조